FDA approves Pfizer's Lyrica for the treatment of the two most common forms of neuropathic pain

NEW YORK, December 31, 2004 - Pfizer Inc said today that it has received approval from the U.S. Food and Drug Administration (FDA) to market LyricaTM (pregabalin capsules) for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) and postherpetic neuralgia (PHN). Lyrica is the first FDA-approved treatment for both of these neuropathic pain states, which are distinctly different from arthritis or musculoskeletal pain.

Developed by Pfizer, Lyrica has a newly defined mechanism of action. Lyrica will be available to physicians and patients in the near future.

"Lyrica is an important new therapy for millions of people suffering from the two most common neuropathic pain conditions as it provides rapid and sustained pain relief," said Dr. Joseph Feczko, president of Worldwide Development at Pfizer. "Lyrica also represents a major achievement in Pfizer's research program and confirms our leadership in bringing life-changing medicines to patients."

Neuropathic pain, one of the most debilitating forms of pain, is caused by nerve damage that can result from underlying conditions, such as diabetes or shingles. Nearly half of the 18 million Americans with diabetes will develop some form of diabetic neuropathy over the course of their disease and about one in six diabetes patients will experience painful diabetic neuropathy. The pain of DPN is often described as burning, tingling, sharp, stabbing, or pins and needles in the feet, legs, hands or arms.

PHN is a complication of shingles, a painful outbreak of rash or blisters on the skin caused by a reactivation of the same virus that causes chicken pox. Each year, about 150,000 Americans develop PHN, which is often characterized as constant stabbing, burning, or electric shock-like sensation.

The efficacy of Lyrica was established in six double-blind, placebo-controlled trials, three involving patients with DPN and three involving patients with

Contact: Rebecca Hamm

Page: 1 2

Related medicine news :

1. FDA approves Enablex for treatment of overactive bladder
2. FDA approves Fosrenol(R) in end-stage renal disease (ESRD) patients
3. FDA approves Adderall XR (R) to treat ADHD in adults
4. FDA approves EPZICOM
5. FDA approves new labelling for Seroquel in bioplar mania
6. FDA approves Enbrel to treat psoriasis
7. FDA approves Climara Pro to treat menopause symptoms
8. FDA approves new approach to schizophrenia treatment
9. FDA approves new HIV protease inhibitor, Lexiva (TM)
10. FDA approves Wellbutrin XL(TM)
11. FDA approves Baxters ADVATE for the treatment of hemophilia A

Post Your Comments:

(Date:12/1/2015)... ... 01, 2015 , ... TCS Healthcare Technologies (TCS), a leading ... arenas, is pleased to announce that VIP Care Services, a Caprock Health Group ... ACUITY Complete Care™ Management to back their collaborative catastrophic case management initiatives. ACUITY ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... With ... footage, and with full control over customization, the possibilities are truly endless, all with ... position randomization, overlay depth position, vertical flip, horizontal flip, depth of field and more, ...
(Date:12/1/2015)... ... December 01, 2015 , ... Tympani Inc., announced today ... status from Cisco. This designation recognizes Tympani as having fulfilled the training requirements ... targeted to the high-end enterprise contact center marketplace. , Ed Kapelinski, President of ...
(Date:11/30/2015)... (PRWEB) , ... December 01, 2015 , ... The Turks ... Journal, one of the leading digital news sites highlighting Caribbean destinations, has published five ... While much of North America shivers under chilly grey skies or worse, it's ...
(Date:11/30/2015)... Los Angeles, California (PRWEB) , ... November 30, ... ... in all the programs of the19th Bi-National Convention of the Federation of Philippine ... Resort and Casino in Las Vegas, Nevada. , 1Heart Caregiver Services, as ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... November 30, 2015 global cell culture market ... bn to US$11.3 bn by 2022 at a CAGR of 7.1% ... to grow from its 2013 value of US$6.1 bn to US$11.3 ... Transparency Market Research has announced the release of a new ... the report, titled ,Cell Culture Market - Global Industry Analysis, Size, ...
(Date:11/30/2015)... Nov. 30, 2015 Nautilus Medical Inc. today ... Management platform ( www.matrixray.com ). The release of MatrixRay ... RSNA 2015 (Radiology Society North America) in ... the U.S. --> --> ... enables access to radiology studies worldwide via a peer-to-peer ...
(Date:11/30/2015)... BANNOCKBURN, Ill. , Nov. 30, 2015 ... ), a global biopharmaceutical leader dedicated to ... diseases and underserved medical conditions, today announced ... [Antihemophilic Factor (Recombinant), PEGylated], an extended circulating ... hemophilia A based on full-length ADVATE [Antihemophilic ...
Breaking Medicine Technology:
Cached News: